This multicenter retrospective real-world study evaluated neoadjuvant disitamab vedotin (RC48), a HER2-directed antibody...

The publication reviews the evolving treatment landscape for localized muscle-invasive bladder cancer. Traditionally man...

This study presents a deep learning approach using convolutional neural networks and transformer-based models to classif...

The FDA approval of Inlexzo (gemcitabine intravesical system) marks a significant advance in bladder-sparing treatment f...

This review focuses on the transformative impact of antibody-drug conjugates (ADCs), specifically enfortumab vedotin and...

This publication reviews the rapidly evolving management of muscle-invasive bladder cancer (MIBC), highlighting the crit...